Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Exclusion Criteria

• •\* Subject has an exclusionary headache, joint, pain, connective tissue, or developmental disorder.
• •Subject has an exclusionary history of trauma, surgery, or radiation treatment to the head and neck.
• •Body Mass Index ≥ 33kg/m2.
• •Subject history of exclusionary medical conditions such as HIV disease, cardiovascular conditions, uncontrolled hypertension or diabetes, psychiatric conditions, drug or alcohol abuse, malignancies, drug allergies, or any significant and/or unstable medical conditions.
• •Subjects taking/using excluded therapies.
• •Participation in clinical trial with non-biological investigational agents or investigational interventional treatments.
• •Subjects who have previously participated in any BHV-3000/ BMS-927711/ rimegepant study.
• •Planned participation in any other investigational clinical trial while participating in this clinical trial.